GLP-1semaglutidetirzepatidesarcopenianutrition

Advances in Therapy issues correction to GLP-1 protein intake and sarcopenia review

The corrected paper by Prokopidis and colleagues addresses protein intake deficiency risk in patients treated with GLP-1 and dual GIP/GLP-1 receptor agonists.

By Maren Holt · Senior Reporter, GLP-1

Oct 8 20:00 ETSource: Advances in therapy

The wire

01Advances in Therapy published a correction on 9 October 2026 to a review by Prokopidis, Cacciatore, Anton and co-authors on protein intake deficiency during GLP-1 and GIP/GLP-1 receptor agonist treatment.
02Clinicians managing incretin patients at risk of secondary sarcopenia rely on this review when setting protein and resistance-training guidance during rapid weight loss.
03The notice is a correction rather than new data; readers should check the publisher's record for what specifically changed in the article.

From the source

Correction: Risk of protein intake deficiency during treatment with GLP-1 and GIP/GLP-1 receptor agonists: considerations for secondary sarcopenia
Advances in therapy · 2026 Oct 9 · Prokopidis K, Cacciatore S, Anton SD et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42853534/